Background: Statins are effective for patients with decreased low-density lipoprotein therapy.
Objective: The aim is to compare atorvastatin versus rosuvastatin on secondary percutaneous coronary intervention
(PCI) rate and explore risk factors in coronary heart disease (CHD) patients.
Methods: A cohort study with 283 CHD subjects was launched from 2011 to 2015. Cox proportional hazards regression
model, Receiver Operating Characteristic (ROC) and nomogram were used to compare the effect of atorvastatin
and rosuvastatin on secondary PCI rate and disease risk factors. Even why the two statins had different effects based
on gene expression profile analysis has been explored.
Results: Gene FFA (Freely fatty acid), AST (Aspartate Transaminase) and ALT (Alanine transaminase) showed the
statistical difference between the four statin groups (P<0.05). In the AA group (Continuous Atorvastatin usage),
albumin was a risk factor (Hazard Ratio (HR):1.076, 95%CI (1.001, 1.162), p<0.05). In the AR group (Start with
Atorvastatin usage, then change to Rosuvastatin usage), ApoA was a protective factor (HR:0.004, 95%CI (0.001,
0.665), p<0.05). GLB (Galactosidase Beta) was a risk factor (HR:1.262, 95%CI (1.010, 1.576), p<0.05). In RR group
(Continuous Rosuvastatin usage), ApoE was a protective factor (HR:0.943, 95%CI (0.890, 1.000), p<0.05). ALT was
a risk factor (HR:1.030, 95%CI (1.000, 1.060), p<0.05).
Conclusion: Patients in the RA group had the lowest secondary PCI rate. ALT was a risk factor in the RR group.
Gene Gpt (Glutamic Pyruvic Transaminase) encoded for one subtype of ALT had a significantly different expression
in different statin groups.